Mural Oncology PLC
NASDAQ:MURA
Intrinsic Value
Mural Oncology PLC is a IE-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one MURA stock under the Base Case scenario is 16.23 USD. Compared to the current market price of 3.76 USD, Mural Oncology PLC is Undervalued by 77%.
Valuation Backtest
Mural Oncology PLC
Run backtest to discover the historical profit from buying and selling MURA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Mural Oncology PLC
| Current Assets | 277.3m |
| Cash & Short-Term Investments | 270.9m |
| Receivables | 5.5m |
| Other Current Assets | 937k |
| Non-Current Assets | 24.4m |
| PP&E | 24.2m |
| Other Non-Current Assets | 258k |
| Current Liabilities | 29m |
| Accounts Payable | 6m |
| Accrued Liabilities | 23m |
| Non-Current Liabilities | 8.9m |
| Other Non-Current Liabilities | 8.9m |
Earnings Waterfall
Mural Oncology PLC
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-196.2m
USD
|
|
Operating Income
|
-196.2m
USD
|
|
Other Expenses
|
-11.2m
USD
|
|
Net Income
|
-207.4m
USD
|
Free Cash Flow Analysis
Mural Oncology PLC
MURA Profitability Score
Profitability Due Diligence
Mural Oncology PLC's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Mural Oncology PLC's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
MURA Solvency Score
Solvency Due Diligence
Mural Oncology PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Mural Oncology PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MURA Price Targets Summary
Mural Oncology PLC
According to Wall Street analysts, the average 1-year price target for MURA is 13.26 USD with a low forecast of 13.13 USD and a high forecast of 13.65 USD.
Shareholder Return
MURA Price
Mural Oncology PLC
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -41% |
| Market Capitalization | 62.8m USD |
| Shares Outstanding | 16 690 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mural Oncology PLC is a IE-based company operating in Biotechnology industry. Mural Oncology plc is a clinical-stage oncology company. The firm is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Contact
IPO
Employees
Officers
The intrinsic value of one MURA stock under the Base Case scenario is 16.23 USD.
Compared to the current market price of 3.76 USD, Mural Oncology PLC is Undervalued by 77%.
You don't have any saved screeners yet
